Epidermal growth factor receptor and variant III targeted immunotherapy.

Published

Journal Article (Review)

Immunotherapeutic approaches to cancer have shown remarkable promise. A critical barrier to successfully executing such immune-mediated interventions is the selection of safe yet immunogenic targets. As patient deaths have occurred when tumor-associated antigens shared by normal tissue have been targeted by strong cellular immunotherapeutic platforms, route of delivery, target selection and the immune-mediated approach undertaken must work together to maximize efficacy with safety. Selected tumor-specific targets can spare potential toxicity to normal tissue; however, they are far less common than tumor-associated antigens and may not be present on all patients. In the context of immunotherapy for high-grade glioma, 2 of the most prominently studied antigens are the tumor-associated epidermal growth factor receptor and its tumor-specific genetic deletion variant III. In this review, we will summarize the immune-mediated strategies employed against these targets as well as the caveats particular to these approaches.

Full Text

Duke Authors

Cited Authors

  • Congdon, KL; Gedeon, PC; Suryadevara, CM; Caruso, HG; Cooper, LJN; Heimberger, AB; Sampson, JH

Published Date

  • October 2014

Published In

Volume / Issue

  • 16 Suppl 8 /

Start / End Page

  • viii20 - viii25

PubMed ID

  • 25342601

Pubmed Central ID

  • 25342601

Electronic International Standard Serial Number (EISSN)

  • 1523-5866

Digital Object Identifier (DOI)

  • 10.1093/neuonc/nou236

Language

  • eng

Conference Location

  • England